Form 4: AngioDynamics CFO Reports Routine Stock Dispositions for Tax Obligations

AngioDynamics' Executive Vice President and CFO, Stephen A. Trowbridge, reported the disposition of 3,969 shares of common stock over three days to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Stephen A. Trowbridge, the Executive Vice President and Chief Financial Officer of AngioDynamics Inc. (ANGO), reported changes in his beneficial ownership of the company's common stock.
• On July 19, 2025, 2,585 shares of common stock were disposed of at a price of $8.69 per share.
• On July 20, 2025, an additional 717 shares of common stock were disposed of at a price of $8.69 per share.
• On July 21, 2025, 667 shares of common stock were disposed of at a price of $8.99 per share.
• The total number of shares disposed across these three transactions was 3,969.
• These dispositions were exempt transactions made solely to satisfy tax withholding obligations arising from the pre-determined vesting of restricted stock units (RSUs) granted to Mr. Trowbridge.
• Following these transactions, Stephen A. Trowbridge beneficially owns 255,739 shares of AngioDynamics common stock.

Sentiment

Score: 5

Explanation: The filing reports routine, non-discretionary stock dispositions by an insider to cover tax obligations related to RSU vesting. This is a neutral event and does not reflect a change in sentiment towards the company or its prospects.

Positives

• The transactions confirm the vesting of restricted stock units, indicating that compensation plans are progressing as scheduled.
• The dispositions are routine and non-discretionary, made to cover tax liabilities, which is a standard practice for equity compensation.

Negatives

• No inherent negatives are present as the dispositions are routine and for tax purposes, not indicative of a lack of confidence in the company.

Risks

• No new risks or potential future challenges were mentioned in this specific filing.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• The dispositions were made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units.

Industry Context

This insider transaction report is specific to an executive's equity compensation and does not provide broader industry trends or competitive analysis.

Comparison to Industry Standards

• The practice of disposing of shares to cover tax withholding obligations upon the vesting of restricted stock units is a standard and common procedure across publicly traded companies, particularly in the medical technology and healthcare sectors where equity compensation is prevalent.
• This type of transaction is not indicative of a discretionary sale based on market sentiment or company performance, aligning with typical compensation structures seen in companies comparable to AngioDynamics.

Stakeholder Impact

• Shareholders: Minimal impact, as these are routine, non-discretionary sales for tax purposes and do not signal a change in management's confidence or company fundamentals.
• Employees: Confirms the regular vesting of equity compensation, which can be seen as a positive for employee incentive programs.

Next Steps

• No specific future actions, events, or milestones are mentioned in this filing beyond the completion of these transactions.

Key Dates

Recommendation

The filing details routine, non-discretionary sales by an executive to cover tax obligations associated with the vesting of restricted stock units. This type of transaction is common and does not indicate any change in the company's fundamentals or the executive's confidence, thus providing no new basis for a change in investment recommendation.

Keywords

AngioDynamics, ANGO, Form 4, Insider Transaction, Stock Disposition, Restricted Stock Units, RSU Vesting, Tax Withholding, Stephen A. Trowbridge, Executive Compensation